Sanofi Says Nexviazyme Was Well Tolerated With Manageable Infusion-Associated Reactions In 29.4% Of Baby-COMET Participants

Sanofi SA Sponsored ADR

Sanofi SA Sponsored ADR

SNY

0.00

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

  • Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study
  • Sanofi intends to submit the data to support a regulatory application in the US for the treatment of infantile-onset Pompe disease
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.